Welcome on the Necker-Enfants Malades Institute website

Understanding oncogenic maturational arrest in order to identify specific differentiation therapy

from basic science:
  • deregulated human T lymphopoiesis
to the translational research:
  • leukemia
  • lymphoma
Elizabeth Macintyre
Vahid Asnafi
Normal and pathological lymphoid differentiation

Elizabeth Macintyre, M.D-PhD FRCP/Path is Professor of Hematology at the Paris Descartes Medical School. She trained in internal Medicine and clinical and laboratory Hematology in the UK (Newcastle and UCL), did her PhD in Paris (St. Louis) and her post-doctoral fellowship in Harvard. She joined the Medical Faculty at Descartes in 1992 and has headed the Hematology Laboratory and the integrated Hematopathology Cancer programmes since 1999 and 2007, respectively.

Vahid Asnafi, M.D-PhD studied Medicine at Paris Descartes before specializing in laboratory Hematology. He obtained his PhD at Descartes in 2003 before doing his post-doctoral studies with Pierre Ferrier at CIML, Marseille. Returning to Necker in 2005, he was appointed full Professor of Hematology in 2012 and now heads the Onco-Hématology laboratory and well as co-directing the "Normal and Pathological Lymphoid Differentiation Team" at INEM


We study molecular mechanisms controlling TCR VDJ rearrangements during human T-cell ontogeny and their implication in (epi)genetic deregulation in T-lymphoid oncogenesis, in order to develop targeted therapeutics for leukemia and lymphoma.


Our research essentially involves analysis of the mechanisms controlling human T lymphoid ontogeny and oncogenic transformation in immature T lymphoid malignancies, particularly T-cell lymphoblastic acute leukemias (T-ALL) and lymphomas (T-LBL).

T-ALLs are malignant clonal proliferations arrested at specific stages of thymic differentiation. Oncogenic deregulation and physiological T lymphopoiesis, including the mechanisms regulating the somatic rearrangements leading to assembly of a T Cell Receptor (TCR), are intimately linked, which implies the contribution of physiological proliferative/apoptotic signals to the oncogenic process.

We have developed cellular and molecular characterisation of lymphoid malignancies in close collaboration with clinical cooperative and fundamental cognitive research groups in order to ensure optimal human tissue resource management and valorisation. All research projects are based on the principal that unravelling oncogenic pathways with an aim to improving treatment requires in-depth understanding of normal development of the system which has undergone deregulated tissue homeostasis.

These studies are possible due to close collaboration with the adult (Group for Research in Adult ALL or GRAALL and Lymphoma Study Association or LYSA) and pediatric (Société Française des Cancers de l’Enfant or SFCE Leukemia and Lymphoma committees) clinical cooperative groups, and with a variety of European networks, such as the EuroFLOW, EuroMRD, EuroClonality and Blueprint consortia.

Research objectives

Cellular and molecular characterization of lymphoid malignancies, with particular emphasis on T lymphoid oncogenesis:

  1. Read the language of antigen receptor (Immunoglobulin and T Cell Receptor) rearrangements in order to:
    • understand maturation arrest and lineage affiliation in order to improve classification of lymphoid malignancies
    • explore the potential oncogenic role of deregulated receptor rearrangements in the development of lymphoid malignancies
    • analyse TCR signalling function in T lymphoid oncogenesis
    • identify the potential for therapeutic correction of blocked lymphoid maturation secondary to deregulated receptor rearrangement
    • explore the mechanisms of action of Homeotic proteins during normal and pathological thymopoiesis
    • Explore the epigenetic regulation of human VDJ rearrangements during T lymphoid development (Blueprint)
  2. Explore Immature T/My/NK/ILC disorders in order to explore the interface between the lymphoid and myeloid lineages
  3. Study the Role of cytokine receptors, NOTCH1/FBXW7 pathway deregulation and aberrant signalling pathways in T-lymphoid oncogenesis
  4. Use innovative cellular and molecular techniques in order to improve integrated management of patients with leukaemia and lymphoma at diagnosis and follow-up, with particular emphasis on:
    • Ig/TCR markers for minimal residual disease personalized management in ALL and NHL
    • Multiparameter flow cytometry
    • Digital droplet quantification
    • High-throughput somatic onco- and immuno-genetics at diagnosis and follow-up

5 main publications

  • Trinquand A et al. (2016) Triggering the TCR developmental checkpoint activates a therapeutically targetable tumor suppressive pathway in T-cell leukemia. Cancer Discov. Sep;6(9):972-85
  • Malcolm et al. (2016) NPM-ALK mimics thymic pre-TCR expansion requiring transient TCR expression for thymic egress and peripheral ALCL Nature Communications. 7:10087
  • Cieslak A et al. (2014) RUNX1 dependent RAG1 deposition instigates Human TCRα locus rearrangement. J Exp Med. Aug 25;211(9):1821-32
  • Trinquand A. et al. (2013) Towards a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-ALL: a GRAALL Study. Journal of clinical oncology Dec 1;31(34):4333-42
  • Dadi S et al. TLX homeodomain oncogenes mediate T-cell maturation arrest in T-ALL via interaction with ETS1 and suppression of TCRα gene expression. Cancer Cell. Apr 17;21(4):563-76

Cinq publications originales majeures

  • Bond J, Graux C, Lhermitte L, Lara D, Cluzeau T, Leguay T, Cieslak A, Trinquand A, Pastoret C, Belhocine M, Spicuglia S, Lheritier V, Leprêtre S, Thomas X, Huguet F, Ifrah N, Dombret H, Macintyre E, Boissel N, Asnafi V. (2017). Early Response-Based Therapy Stratification Improves Survival in Adult Early Thymic Precursor Acute Lymphoblastic Leukemia: A Group for Research on Adult Acute Lymphoblastic Leukemia Study. J Clin Oncol. Aug 10;35(23):2683-2691. doi: 10.1200/JCO.2016.71.8585
  • Petit A, Trinquand A, Chevret S, Ballerini P, Cayuela JM, Grardel N, Touzart A, Brethon B, Lapillonne H, Schmitt C, Thouvenin S, Michel G, Preudhomme C, Soulier J, Leverger G, Macintyre E, Baruchel A, Asnafi V. (2018). Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-Cell Acute Lymphoblastic LeukemiaBlood. Jan 18;131(3):289-300. doi: 10.1182/blood-2017-04-77882
  • Cieslak A, Charbonnier G, Tesio M, Mathieu E, Belhocine M, Touzart A, Smith C, Hypolite G, Andrieu GP, Martens JHA, Janssen-Megens E, Gut M, Gut I, Boissel N, Petit A, Puthier D, Macintyre E, Stunnenberg HG, Spicuglia S, Asnafi V. (2020). Blueprint of human thymopoiesis reveals molecular mechanisms of stage-specific TCR enhancer activationJ Exp Med. Sep 7;217(9):e20192360. doi: 10.1084/jem.20192360
  • Touzart A, Mayakonda A, Smith C, Hey J, Toth R, Cieslak A, Andrieu GP, Tran Quang C, Latiri M, Ghysdael J, Spicuglia S, Dombret H, Ifrah N, Macintyre E, Lutsik P, Boissel N, Plass C and Asnafi V. (2021). Epigenetic blueprint identifies poor outcome and hypomethylating agent-responsive T-ALL subgroup. Sci Transl Med. May 26;13(595):eabc4834. doi: 10.1126/scitranslmed.abc4834
  •  Andrieu GP, Kohn M, Simonin M, Smith C, Cieslak A, Dourthe ME, Charbonnier G, Graux C, Rigal-Huguet F, Lheritier V, Dombret H, Spicuglia S, Rousselot P, Boissel N, Asnafi V. (2021). PRC2 loss of function confers a targetable vulnerability to BET proteins in T-ALLBlood. Nov 11;138(19):1855-1869. doi: 10.1182/blood.2020010081

    Liste des publications


  • Blueprint of human thymopoiesis reveals molecular mechanisms of stage-specific TCR enhancer activation.
    Cieslak A, Charbonnier G, Tesio M, Mathieu E, Belhocine M, Touzart A, Smith C, Hypolite G, Andrieu GP, Martens JHA, Janssen-Megens E, Gut M, Gut I, Boissel N, Petit A, Puthier D, Macintyre E, Stunnenberg HG, Spicuglia S, Asnafi V.
    J Exp Med. 2020 Sep 7;217(9):e20192360.
  • Preclinical Efficacy of Humanized, non-FcγR Binding Anti-CD3 Antibodies in T-cell Acute Lymphoblastic Leukemia
    Christine Tran Quang , Benedetta Zaniboni , Romain Humeau , Etienne Lengline , Marie-Emilie Dourthe , Rajkumar Ganesan , Sanjaya Singh, Justin M Scheer , Vahid Asnafi, Jacques Ghysdael
    Blood 2020 Jun 1; blood.2019003801. doi: 10.1182/blood.2019003801. Online ahead of print.
  • A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis.
    Bond J, Krzywon A, Lhermitte L, Roumier C, Roggy A, Belhocine M, Kheirallah AA, Villarese P, Hypolite G, Garnache-Ottou F, Castaigne S, Boissel N, Asnafi V, Preudhomme C, Dombret H, Laurenti E, Macintyre E.
    Leukemia. 2020 Jul 13. doi: 10.1038/s41375-020-0965-z. Online ahead of print. PMID: 32655144
  • Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation.
    Kim R, Boissel N, Touzart A, Leguay T, Thonier F, Thomas X, Raffoux E, Huguet F, Villarese P, Fourrage C, Passini L, Hunault M, Lepretre S, Chevallier P, Braun T, Lhéritier V, Chantepie S, Maury S, Escoffre M, Tavernier E, Chalandon Y, Graux C, Macintyre E, Ifrah N, Asnafi V, Dombret H, Lhermitte L; on behalf the GRAALL group.
    Leukemia. 2020 Jan 28. doi: 10.1038/s41375-019-0685-4. [Epub ahead of print] PubMed PMID: 31992840.
  • CBFβ-SMMHC Affects Genome-wide Polycomb Repressive Complex 1 Activity in Acute Myeloid Leukemia.
    Cordonnier G, Mandoli A, Cagnard N, Hypolite G, Lhermitte L, Verhoeyen E, Asnafi V, Dillon N, Macintyre E, Martens JHA, Bond J.
    Cell Rep. 2020 Jan 14;30(2):299-307.e3. doi: 10.1016/j.celrep.2019.12.026. PubMed PMID: 31940477.
  • Caution encouraged in NGS immunogenetic analyses in Acute Lymphoblastic Leukemia.
    Abdo C, Thonier F, Simonin M, Kaltenbach S, Valduga J, Petit A, Brüggemann M, Macintyre EA.
    Blood. 2020 May 21:blood.2020005613. doi:10.1182/blood.2020005613. Epub ahead of print. PMID: 32438392.
  • Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network.
    Drandi D, Alcantara M, Benmaad I, Söhlbrandt A, Lhermitte L, Zaccaria G, Ferrante M, Genuardi E, Mantoan B, Villarese P, Cheminant M, Starza ID, Ciabatti E, Bomben R, Jimenez C, Callanan M, Abdo C, Eckert C, Ribrag V, Cortelazzo S, Dreyling M, Hermine O, Delfau-Larue MH, Pott C, Ladetto M, Ferrero S, Macintyre E.
    Hemasphere. 2020 Apr 3;4(2):e347. doi: 10.1097/HS9.0000000000000347. PMID: 32309784; PMCID: PMC7162081.
  • Reducing Bureaucracy in Clinical Research: A Call for Action.
    Gribben J, Macintyre E, Sonneveld P, Doorduijn J, Gisselbrecht C, Jäger U, Le Gouill S, Rule S, Dreyling M.
    Hemasphere. 2020 Feb 26;4(2):e352. doi: 10.1097/HS9.0000000000000352. PMID: 32309789
  • 2019

  • Low level CpG island promoter methylation predicts a poor outcome in adult T-cell acute lymphoblastic leukemia.
    Touzart A, Boissel N, Belhocine M, Smith C, Graux C, Latiri M, Lhermitte L, Mathieu EL, Huguet F, Lamant L, Ferrier P, Ifrah N, Macintyre E, Dombret H, Asnafi V, Spicuglia S.
    Haematologica. 2019 Sep 19. pii: haematol.2019.223677. doi: 10.3324/haematol.2019.223677. [Epub ahead of print] PubMed PMID: 31537687.
  • Standardization of Flow Cytometric Immunophenotyping for Hematological Malignancies: The FranceFlow Group Experience.
    Solly F, Angelot-Delettre F, Ticchioni M, Geneviève F, Rambaud H, Baseggio L, Plesa A, Debliquis A, Garnache-Ottou F, Roggy A, Campos L, Aanei C, Rosenthal-Allieri A, Georget MT, Lachot S, Jacob MC, Robillard N, Wuilleme S, Andre-Kerneis E, Cornet E, Salaun V, Bennami H, Lhoumeau AC, Arnoulet C, Jacqmin H, Neyman N, Latger-Cannard V, Massin F, Lainey E, Le Garff-Tavernier M, Costopoulos M, Roussel M, Mayeur-Rousse C, Eischen A, Raggeneau V, Derrieux C,Maurer M, Asnafi V, Trinquand A, Brouzes C, Lhermitte L.
    Cytometry A. 2019 Sep;95(9):1008-1018. doi: 10.1002/cyto.a.23844. Epub 2019 Jul 31. PubMed PMID: 31364809.
  • Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemia.
    Alcantara M, Simonin M, Lhermitte L, Touzart A, Dourthe ME, Latiri M, Grardel N, Cayuela JM, Chalandon Y, Graux C, Dombret H, Ifrah N, Petit A, Macintyre E, Baruchel A, Boissel N, Asnafi V.
    Blood Adv. 2019 Jul 9;3(13):1981-1988. doi: 10.1182/bloodadvances.2018028993. PubMed PMID: 31270080; PubMed Central PMCID: PMC6616254.
  • Epigenetic Silencing Affects l-Asparaginase Sensitivity and Predicts Outcome in T-ALL.
    Touzart A, Lengliné E, Latiri M, Belhocine M, Smith C, Thomas X, Spicuglia S, Puthier D, Pflumio F, Leguay T, Graux C, Chalandon Y, Huguet F, Leprêtre S, Ifrah N, Dombret H, Macintyre E, Hunault M, Boissel N, Asnafi V.
    Clin Cancer Res. 2019 Apr 15;25(8):2483-2493. doi: 10.1158/1078-0432.CCR-18-1844. Epub 2019 Jan 18. PubMed PMID: 30659025.
  • DNMT3A mutation is associated with increased age and adverse outcome in adult T-cell acute lymphoblastic leukemia.
    Bond J, Touzart A, Leprêtre S, Graux C, Bargetzi M, Lhermitte L, Hypolite G, Leguay T, Hicheri Y, Guillerm G, Bilger K, Lhéritier V, Hunault M, Huguet F, Chalandon Y, Ifrah N, Macintyre E, Dombret H, Asnafi V, Boissel N.
    Haematologica. 2019 Aug;104(8):1617-1625. doi: 10.3324/haematol.2018.197848. Epub 2019 Jan 17. PubMed PMID: 30655366; PubMed Central PMCID: PMC6669163.
  • A Single-Tube, EuroClonality-Inspired, TRG Clonality Multiplex PCR Aids Management of Patients with Enteropathic Diseases, including from Formaldehyde-Fixed, Paraffin-Embedded Tissues.
    Derrieux C, Trinquand A, Bruneau J, Verkarre V, Lhermitte L, Alcantara M, Villarese P, Meresse B, Sibon D, Hermine O, Brousse N, Molina T, Cellier C, Cerf-Bensussan N, Malamut G, Macintyre E.
    J Mol Diagn. 2019 Jan;21(1):111-122. doi: 10.1016/j.jmoldx.2018.08.006. Epub 2018 Sep 28. PMID: 30268943.
  • 2018

  • The Need for a Consensus Next-generation Sequencing Panel for Mature Lymphoid Malignancies.
    Sujobert P, Le Bris Y, de Leval L, Gros A, Merlio JP, Pastoret C, Huet S, Sarkozy C, Davi F, Callanan M, Thieblemont C, Sibon D, Asnafi V, Preudhomme C, Gaulard P, Jardin F, Salles G, Macintyre E.
    Hemasphere. 2018 Dec 27;3(1):e169. doi: 10.1097/HS9.0000000000000169. eCollection 2019 Feb. PubMed PMID: 31723808; PubMed Central PMCID: PMC6745936.
  • Novel Intergenically Spliced Chimera, NFATC3-PLA2G15, Is Associated with Aggressive T-ALL Biology and Outcome
    Bond J, Tran Quang C, Hypolite G, Belhocine M, Bergon A, Cordonnier G, Ghysdael J, Macintyre E, Boissel N, Spicuglia S, Asnafi V.
    Mol Cancer Res. 2018 Mar;16(3):470-475. doi: 10.1158/1541-7786.MCR-17-0442. Epub 2018 Jan 12. PubMed PMID: 29330284.
  • Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia.
    Petit A, Trinquand A, Chevret S, Ballerini P, Cayuela JM, Grardel N, Touzart A, Brethon B, Lapillonne H, Schmitt C, Thouvenin S, Michel G, Preudhomme C, Soulier J, Landman-Parker J, Leverger G, Macintyre E, Baruchel A, Asnafi V; French Acute Lymphoblastic Leukemia Study Group (FRALLE).
    Blood. 2018 Jan 18;131(3):289-300. doi: 10.1182/blood-2017-04-778829. Epub 2017 Oct 19. PubMed PMID: 29051182.
  • 2017

  • Cordonnier G, Mandoli A, Radhouane A, Hypolite G, Lhermitte L, Belhocine M, Asnafi V, Macintyre E, Martens JH, Fumagalli S, Bond J. Letter to the Editor: CBFβ-SMMHC regulates ribosomal gene transcription and alters ribosome biogenesis. Leukemia. 2017 Feb 15. doi: 10.1038/leu.2017.53. [Epub ahead of print]
  • Costa C, Hypolite G, Bernadin O, Lévy C, Cosset FL, Asnafi V, Macintyre E, Verhoeyen E, Tesio M. Baboon envelope pseudotyped lentiviral vectors: a highly efficient new tool to genetically manipulate T-cell acute lymphoblastic leukaemia-initiating cells. Leukemia. 2017 Jan 13. doi: 10.1038/leu.2016.372. [Epub ahead of print] No abstract available.
  • Sarkozy C, Kaltenbach S, Faurie P, Canioni D, Berger F, Traverse-Glehen A, Ghesquieres H, Salles G, Bachy E, Alyanakian MA, Hermine O, Neven B, Macintyre E, Romana S, Molina TJ, Suarez F, Asnafi V, Bruneau J. Array-CGH predicts prognosis in plasma cell post-transplantation lymphoproliferative disorders. Genes Chromosomes Cancer. 2017 Mar;56(3):221-230.
  • 2016

  • Desjonquères A, Chevallier P, Thomas X, Huguet F, Leguay T, M, Bay JO, Tavernier E, Charbonnier A, Isnard F, Hunault M, Turlure P, Renaud M, Bastié JN, Himberlin C, Lepretre S, Lioure B, Lhéritier V, Asnafi V, Beldjord K, Lafage-Pochitaloff M, Béné MC, Ifrah N, Dombret H. Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study. Blood Cancer J. 2016 Dec 9;6(12):e504. doi: 10.1038/bcj.2016.111.
  • Manchev VT, Bouzid H, Antony-Debré I, Leite B, Meurice G, Droin N, Prebet T, Costello RT, Vainchenker W, Plo I, Diop M, Macintyre E, Asnafi V, Favier R, Baccini V, Raslova H. Acquired TET2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of pre-leukaemic clone resulting in T2-ALL and AML-M0. J Cell Mol Med. 2016 Dec 20. doi: 10.1111/jcmm.13051. [Epub ahead of print]
  • Ribeiro ST, Tesio M, Ribot JC, Macintyre E, Barata JT, Silva-Santos B. Casein kinase 2 controls the survival of normal thymic and leukemic γδ T cells via promotion of AKT signaling. Leukemia. 2016 Dec 16. doi: 10.1038/leu.2016.363. [Epub ahead of print]
  • Ceroi A, Masson D, Roggy A, Roumier C, Chagué C, Gauthier T, Philippe L, Lamarthée B, Angelot-Delettre F, Bonnefoy F, Perruche S, Biichle S, Preudhomme C, Macintyre E, Lagrost L, Garnache-Ottou F, Saas P. LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis. Blood. 2016 Dec 8;128(23):2694-2707.
  • Marçais A, Waast L, Bruneau J, Hanssens K, Asnafi V, Gaulard P, Suarez F, Dubreuil P, Gessain A, Hermine O, Pique C. Adult T cell leukemia aggressivenness correlates with loss of both 5-hydroxymethylcytosine and TET2 expression. Oncotarget. 2016 Nov 26. doi: 10.18632/oncotarget.13665. [Epub ahead of print]
  • Stunnenberg HG; International Human Epigenome Consortium., Hirst M. The International Human Epigenome Consortium: A Blueprint for Scientific Collaboration and Discovery. Cell. 2016 Nov 17;167(5):1145-1149.
  • Malcolm TI, Hodson DJ, Macintyre EA, Turner SD. Challenging perspectives on the cellular origins of lymphoma. Open Biol. 2016 Sep;6(9). pii: 160232.
  • Ettersperger J, Montcuquet N, Malamut G, Guegan N, Lopez-Lastra S, Gayraud S, Reimann C, Vidal E, Cagnard N, Villarese P, Andre-Schmutz I, Gomes Domingues R, Godinho-Silva C, Veiga-Fernandes H, Lhermitte L, Asnafi V, Macintyre E, Cellier C, Beldjord K, Di Santo JP, Cerf-Bensussan N, Meresse B. Interleukin-15-Dependent T-Cell-like Innate Intraepithelial Lymphocytes Develop in the Intestine and Transform into Lymphomas in Celiac Disease. Immunity. 2016 Sep 20;45(3):610-25.
  • Bond J, Domaschenz R, Roman-Trufero M, Sabbattini P, Ferreiros-Vidal I, Gerrard G, Asnafi V, Macintyre E, Merkenschlager M, Dillon N. Direct interaction of Ikaros and Foxp1 modulates expression of the G protein-coupled receptor G2A in B-lymphocytes and acute lymphoblastic leukemia. Oncotarget. 2016 Oct 4;7(40):65923-65936. doi: 10.18632/oncotarget.11688.
  • Trinquand A, Dos Santos NR, Tran Quang C, Rocchetti F, Zaniboni B, Belhocine M, Da Costa de Jesus C, Lhermitte L, Tesio M, Dussiot M, Cosset FL, Verhoeyen E, Pflumio F, Ifrah N, Dombret H, Spicuglia S, Chatenoud L, Gross DA, Hermine O, Macintyre E, Ghysdael J, Asnafi V. Triggering the TCR Developmental Checkpoint Activates a Therapeutically Targetable Tumor Suppressive Pathway in T-cell Leukemia. Cancer Discov. 2016 Sep;6(9):972-85. doi: 10.1158/2159-8290.CD-15-0675.
  • Emadali A, Hoghoughi N, Duley S, Hajmirza A, Verhoeyen E, Cosset FL, Bertrand P, Roumier C, Roggy A, Suchaud-Martin C, Chauvet M, Bertrand S, Hamaidia S, Rousseaux S, Josserand V, Charles J, Templier I, Maeda T, Bruder-Costa J, Chaperot L, Plumas J, Jacob MC, Bonnefoix T, Park S, Gressin R, Tensen CP, Mecucci C, Macintyre E, Leroux D, Brambilla E, Nguyen-Khac F, Luquet I, Penther D, Bastard C, Jardin F, Lefebvre C, Garnache F, Callanan MB. Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms. Blood. 2016 Jun 16;127(24):3040-53.
  • Bond J, Marchand T, Touzart A, Cieslak A, Trinquand A, Sutton L, Radford-Weiss I, Lhermitte L, Spicuglia S, Dombret H, Macintyre E, Ifrah N, Hamel JF, Asnafi V. An early thymic precursor phenotype predicts outcome exclusively in HOXA-overexpressing adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. Haematologica. 2016 Jun;101(6):732-40.
  • Malcolm TI, Villarese P, Fairbairn CJ, Lamant L, Trinquand A, Hook CE, Burke GA, Brugières L, Hughes K, Payet D, Merkel O, Schiefer AI, Ashankyty I, Mian S, Wasik M, Turner M, Kenner L, Asnafi V, Macintyre E, Turner SD. Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress. Nat Commun. 2016 Jan 12;7:10087. doi: 10.1038/ncomms10087.
  • Lepretre S, Touzart A, Vermeulin T, Picquenot JM, Tanguy-Schmidt A, Salles G, Lamy T, Béné MC, Raffoux E, Huguet F, Chevallier P, Bologna S, Bouabdallah R, Benichou J, Brière J, Moreau A, Tallon-Simon V, Seris S, Graux C, Asnafi V, Ifrah N, Macintyre E, Dombret H. Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study. J Clin Oncol. 2016 Feb 20;34(6):572-80. doi: 10.1200/JCO.2015.61.5385.
  • Tesio M, Trinquand A, Macintyre E, Asnafi V. Oncogenic PTEN functions and models in T-cell malignancies. Oncogene. 2016 Jul 28;35(30):3887-96. doi: 10.1038/onc.2015.462. Review.
  • Bond J, Touzart A, Cieslak A, Trinquand A, Marchand T, Escoffre M, Contet A, Muller M, Schmitt C, Fest T, Asnafi V, Macintyre E. NAP1L1-MLLT10 is a rare recurrent translocation that is associated with HOXA activation and poor treatment response in T-cell acute lymphoblastic leukaemia. Br J Haematol. 2016 Aug;174(3):470-3. doi: 10.1111/bjh.13772. No abstract available.
  • Bachy E, Urb M, Chandra S, Robinot R, Bricard G, de Bernard S, Traverse-Glehen A, Gazzo S, Blond O, Khurana A, Baseggio L, Heavican T, Ffrench M, Crispatzu G, Mondière P, Schrader A, Taillardet M, Thaunat O, Martin N, Dalle S, Le Garff-Tavernier M, Salles G, Lachuer J, Hermine O, Asnafi V, Roussel M, Lamy T, Herling M, Iqbal J, Buffat L, Marche PN, Gaulard P, Kronenberg M, Defrance T, Genestier L. CD1d-restricted peripheral T cell lymphoma in mice and humans. J Exp Med. 2016 May 2;213(5):841-57.
  • Lepretre S, Touzart A, Vermeulin T, Picquenot JM, Tanguy-Schmidt A, Salles G, Lamy T, Béné MC, Raffoux E, Huguet F, Chevallier P, Bologna S, Bouabdallah R, Benichou J, Brière J, Moreau A, Tallon-Simon V, Seris S, Graux C, Asnafi V, Ifrah N, Macintyre E, Dombret H. Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study. J Clin Oncol. 2016 Feb 20;34(6):572-80.
  • 2015

  • Minard-Colin V, Brugières L, Reiter A, Cairo MS, Gross TG, Woessmann W, Burkhardt B, Sandlund JT, Williams D, Pillon M, Horibe K, Auperin A, Le Deley MC, Zimmerman M, Perkins SL, Raphael M, Lamant L, Klapper W, Mussolin L, Poirel HA, Macintyre E, Damm-Welk C, Rosolen A, Patte C. Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead. J Clin Oncol. 2015 Sep 20;33(27):2963-74.
  • Dussiau C, Trinquand A, Lhermitte L, Latiri M, Simonin M, Cieslak A, Bedjaoui N, Villarèse P, Verhoeyen E, Dombret H, Ifrah N, Macintyre E, Asnafi V. Targeting IRAK1 in T-cell acute lymphoblastic leukemia. Oncotarget. 2015 Aug 7;6(22):18956-65.
  • Delfau-Larue MH, Klapper W, Berger F, Jardin F, Briere J, Salles G, Casasnovas O, Feugier P, Haioun C, Ribrag V, Thieblemont C, Unterhalt M, Dreyling M, Macintyre E, Pott C, Hermine O, Hoster E; European Mantle Cell Lymphoma Network. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood. 2015 Jul 30;126(5):604-11.
  • Tesio M, Tang Y, Müdder K, Saini M, von Paleske L, Macintyre E, Pasparakis M, Waisman A, Trumpp A. Hematopoietic stem cell quiescence and function are controlled by the CYLD-TRAF2-p38MAPK pathway. J Exp Med. 2015 Apr 6;212(4):525-38.
  • Navarro JM, Touzart A, Pradel LC, Loosveld M, Koubi M, Fenouil R, Le Noir S, Maqbool MA, Morgado E, Gregoire C, Jaeger S, Mamessier E, Pignon C, Hacein-Bey-Abina S, Malissen B, Gut M, Gut IG, Dombret H, Macintyre EA, Howe SJ, Gaspar HB, Thrasher AJ, Ifrah N, Payet-Bornet D, Duprez E, Andrau JC, Asnafi V, Nadel B. Site- and allele-specific polycomb dysregulation in T-cell leukaemia. Nat Commun. 2015 Jan 23;6:6094.
  • Dhédin N, Huynh A, Maury S, Tabrizi R, Beldjord K, Asnafi V, Thomas X, Chevallier P, Nguyen S, Coiteux V, Bourhis JH, Hichri Y, Escoffre-Barbe M, Reman O, Graux C, Chalandon Y, Blaise D, Schanz U, Lhéritier V, Cahn JY, Dombret H, Ifrah N; GRAALL group. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Blood. 2015 Apr 16;125(16):2486-96.
  • Barete S, Lortholary O, Damaj G, Hirsch I, Chandesris MO, Elie C, Hamidou M, Durieu I, Suarez F, Grosbois B, Limal N, Gyan E, Larroche C, Guillet G, Kahn JE, Casassus P, Amazzough K, Coignard-Biehler H, Georgin-Lavialle S, Lhermitte L ,Fraitag S, Canioni D, Dubreuil P, Hermine O. Long-term efficacy and safety ofcladribine (2-CdA) in adult patients with mastocytosis. Blood. 2015 May 22. pii: blood-2014-12-614743. [Epub ahead of print] PubMed PMID: 26002962.
  • Kalina T, Flores-Montero J, Lecrevisse Q, Pedreira CE, van der Velden VH, Novakova M, Mejstrikova E, Hrusak O, Böttcher S, Karsch D, Sędek Ł, Trinquand A, Boeckx N, Caetano J, Asnafi V, Lucio P, Lima M, Helena Santos A, Bonaccorso P, van der Sluijs-Gelling AJ, Langerak AW, Martin-Ayuso M, Szczepański T, van Dongen JJ, Orfao A. Quality assessment program for EuroFlow protocols: summary results of four-year (2010-2013) quality assurance rounds. Cytometry A. 2015 Feb;87(2):145-56.
  • Tesio M, Trinquand A, Macintyre E, Asnafi V. Oncogenic PTEN functions and models in T-cell malignancies. Oncogene. 2015 Nov 30. doi: 10.1038/onc.2015.462. [Epub ahead of print] Review.
  • Permanent researcher
    Guillaume Andrieu
    +33 (0)1 40 61 54 36
    Vahid Asnafi
    Professor Researcher
    +33 (0)1 44 49 49 14
    Chantal Brouzes
    +33 (0)1 44 49 49 32
    Bruno Canque
    Emilie Dourthe
    +33 (0)1 40 61 54 36
    Sophie Kaltenbach
    +33 (0)1 44 49 49 69
    Ludovic Lhermitte
    +33 (0)1 44 49 49 33
    Elizabeth Macintyre
    Professor Researcher
    +33 (0)1 44 49 49 47
    Ambroise Marcais
    Aurore Touzart
    Professor Researcher
    +33 (0)1 44 49 40 98
    Non permanent researcher
    Omer Beganovic
    Marianne Courgeon
    Lucien Courtois
    +33 (0)1 40 61 54 36
    Permanent engineer
    Agata Cieslak
    +33 (0)1 40 61 54 36
    Mélodie Culot
    Patrick Villarese
    +33 (0)1 44 49 49 41
    Non permanent engineer
    Jérôme Doss
    Nicolas Gaidot
    +33 (0)1 40 61 54 36
    Camille Gillet
    +33 (0)1 40 61 54 35
    Grégoire Hure
    Mélissandre Trenchand
    Post-doctoral degree
    Khaldoun Gharzeddine
    Post-Doctoral Researcher
    Charlotte Smith
    Post-Doctoral Researcher
    +33 (0)1 40 61 54 36
    Manon Delafoy
    PhD Student
    +33 (0)1 40 61 54 36
    Emilie Deruelle
    PhD Student
    +33 (0)1 40 61 54 36
    El Mehdi Latiri
    PhD Student
    +33 (0)1 40 61 54 35
    Valentine Louis
    PhD Student
    Antoine Pinton
    PhD Student
    Thomas Steimle
    PhD Student
    +33 (0)1 44 49 49 41
    Amandine Cheval
    Inès Kassou
    Agathe Spaeth
    Julien Staub

    Notice: Undefined variable: contact_addr in /homepages/40/d483507699/htdocs/location.php on line 21
    HRH Princess Caroline of Hanover, who through the Princess Grace Foundation, already supports medical research and anything that helps to relieve the sick children in France and around the world, has agreed to commit to our side so that our Center of Molecular medicine continues to meet the current challenges and fight diseases, and in particular the ones affecting children.

    INEM - Organigramme